分析分析分析PT Indofarma (Persero)和Tbk财务表现的利润率

Santa Maria Manungkalit, Dimas Sumitra Danisworo, Banter Laksana
{"title":"分析分析分析PT Indofarma (Persero)和Tbk财务表现的利润率","authors":"Santa Maria Manungkalit, Dimas Sumitra Danisworo, Banter Laksana","doi":"10.35313/ijem.v2i3.3739","DOIUrl":null,"url":null,"abstract":"This study aims to analyze the financial performance of PT. Indofarma, Tbk using the profitability ratio approach. Performance research variables use profitability ratios which include Return on Asset Ratio (ROA), Return on Equity Ratio (ROE), and Net Profit Margin (NPM). The method in this study uses quantitative research with a descriptive approach. The focus of this research includes how the profitability ratio analysis can show the financial performance of PT.Indofarma from 2016 to 2020. Based on the results of the company's financial data processing, seen from the company's Return on Assets , it can be concluded that the company's financial performance is not good and the company is less effective in using assets. his. Based on Return on Equity from 2016 to 2020 can seen that the company's financial performance is not good because it is still below the industry standard of 40%. And the value of the Net Profit Margin is said to be still not good because it has not met the industry standard average of 20%. Overall, the financial performance of PT. Indofarma for the last 5 years is not good when compared to industry standards. However, in 2019 and 2020, the company began to increase its sales so that the company's financial performance began to improve even though it was still far from the industry average.","PeriodicalId":314344,"journal":{"name":"Indonesian Journal of Economics and Management","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Analisis Rasio Profitabilitas untuk Menilai Kinerja Keuangan PT Indofarma (Persero),Tbk\",\"authors\":\"Santa Maria Manungkalit, Dimas Sumitra Danisworo, Banter Laksana\",\"doi\":\"10.35313/ijem.v2i3.3739\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This study aims to analyze the financial performance of PT. Indofarma, Tbk using the profitability ratio approach. Performance research variables use profitability ratios which include Return on Asset Ratio (ROA), Return on Equity Ratio (ROE), and Net Profit Margin (NPM). The method in this study uses quantitative research with a descriptive approach. The focus of this research includes how the profitability ratio analysis can show the financial performance of PT.Indofarma from 2016 to 2020. Based on the results of the company's financial data processing, seen from the company's Return on Assets , it can be concluded that the company's financial performance is not good and the company is less effective in using assets. his. Based on Return on Equity from 2016 to 2020 can seen that the company's financial performance is not good because it is still below the industry standard of 40%. And the value of the Net Profit Margin is said to be still not good because it has not met the industry standard average of 20%. Overall, the financial performance of PT. Indofarma for the last 5 years is not good when compared to industry standards. However, in 2019 and 2020, the company began to increase its sales so that the company's financial performance began to improve even though it was still far from the industry average.\",\"PeriodicalId\":314344,\"journal\":{\"name\":\"Indonesian Journal of Economics and Management\",\"volume\":\"37 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indonesian Journal of Economics and Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35313/ijem.v2i3.3739\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indonesian Journal of Economics and Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35313/ijem.v2i3.3739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本研究旨在运用盈利能力比率法分析PT. Indofarma, Tbk的财务绩效。绩效研究变量使用盈利比率,包括资产收益率(ROA),股本收益率(ROE)和净利润率(NPM)。本研究采用定量研究和描述性研究相结合的方法。本研究的重点包括盈利能力比率分析如何显示PT.Indofarma 2016 - 2020年的财务业绩。根据公司财务数据处理的结果,从公司的资产收益率来看,可以得出公司财务业绩不佳,公司资产使用效率较低的结论。他的从2016年到2020年的净资产收益率可以看出,公司的财务表现并不好,因为它仍然低于40%的行业标准。据说,净利润率的价值仍然不好,因为它没有达到20%的行业平均标准。总的来说,与行业标准相比,PT. Indofarma过去5年的财务表现并不好。然而,在2019年和2020年,公司的销售额开始增加,公司的财务业绩开始改善,尽管仍远低于行业平均水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Analisis Rasio Profitabilitas untuk Menilai Kinerja Keuangan PT Indofarma (Persero),Tbk
This study aims to analyze the financial performance of PT. Indofarma, Tbk using the profitability ratio approach. Performance research variables use profitability ratios which include Return on Asset Ratio (ROA), Return on Equity Ratio (ROE), and Net Profit Margin (NPM). The method in this study uses quantitative research with a descriptive approach. The focus of this research includes how the profitability ratio analysis can show the financial performance of PT.Indofarma from 2016 to 2020. Based on the results of the company's financial data processing, seen from the company's Return on Assets , it can be concluded that the company's financial performance is not good and the company is less effective in using assets. his. Based on Return on Equity from 2016 to 2020 can seen that the company's financial performance is not good because it is still below the industry standard of 40%. And the value of the Net Profit Margin is said to be still not good because it has not met the industry standard average of 20%. Overall, the financial performance of PT. Indofarma for the last 5 years is not good when compared to industry standards. However, in 2019 and 2020, the company began to increase its sales so that the company's financial performance began to improve even though it was still far from the industry average.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信